Cholera – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Cholera – Drugs In Development, 2024 report and make more profitable business decisions.
Cholera is an acute infectious disease caused by a bacterium, Vibrio cholera, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after infection. Symptoms are often mild, they can be very serious. Signs and symptoms of cholera include rapid heart rate, loss of skin elasticity, low blood pressure, thirst, and muscle cramps. If not treated, this can lead to shock and death in a matter of hours.
The Cholera drugs in development market research report provide comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cholera and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Cholera | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 17 molecules, with 6 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Cholera therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Cholera pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Cholera treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Augusta UniversityBavarian Nordic AS
Bharat Biotech Ltd
Boston Children's Hospital
Brigham and Women's Hospital
Finlay Institute
Global BioLife Inc Ltd
Howard Hughes Medical Institute
International Vaccine Institute
Napo Pharmaceuticals Inc
Ostrich Pharma USA Inc
Princeton University
Stanford University
The Institute of Medical Science The University of Tokyo
Tufts University
Vanda Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Cholera reports